AU2016238246B2 - Multi-valent hepatitis B virus antigen binding molecules and uses thereof - Google Patents

Multi-valent hepatitis B virus antigen binding molecules and uses thereof Download PDF

Info

Publication number
AU2016238246B2
AU2016238246B2 AU2016238246A AU2016238246A AU2016238246B2 AU 2016238246 B2 AU2016238246 B2 AU 2016238246B2 AU 2016238246 A AU2016238246 A AU 2016238246A AU 2016238246 A AU2016238246 A AU 2016238246A AU 2016238246 B2 AU2016238246 B2 AU 2016238246B2
Authority
AU
Australia
Prior art keywords
seq
antibody
binding
hbv
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2016238246A
Other languages
English (en)
Other versions
AU2016238246A1 (en
Inventor
Ramesh Baliga
Stephen F. Carroll
Bruce A. Keyt
Dean Ng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IGM Biosciences Inc
Original Assignee
IGM Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IGM Biosciences Inc filed Critical IGM Biosciences Inc
Publication of AU2016238246A1 publication Critical patent/AU2016238246A1/en
Assigned to IGM BIOSCIENCES A/S reassignment IGM BIOSCIENCES A/S Request for Assignment Assignors: IGM BIOSCIENCES, INC.
Assigned to IGM BIOSCIENCES, INC. reassignment IGM BIOSCIENCES, INC. Request for Assignment Assignors: IGM BIOSCIENCES A/S
Application granted granted Critical
Publication of AU2016238246B2 publication Critical patent/AU2016238246B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/082—Hepadnaviridae (F), e.g. hepatitis B virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5761—Hepatitis B
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/02—Hepadnaviridae, e.g. hepatitis B virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
AU2016238246A 2015-03-25 2016-03-25 Multi-valent hepatitis B virus antigen binding molecules and uses thereof Ceased AU2016238246B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562137881P 2015-03-25 2015-03-25
US62/137,881 2015-03-25
PCT/US2016/024348 WO2016154593A1 (en) 2015-03-25 2016-03-25 Multi-valent hepatitis b virus antigen binding molecules and uses thereof

Publications (2)

Publication Number Publication Date
AU2016238246A1 AU2016238246A1 (en) 2017-10-12
AU2016238246B2 true AU2016238246B2 (en) 2021-05-13

Family

ID=56977811

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016238246A Ceased AU2016238246B2 (en) 2015-03-25 2016-03-25 Multi-valent hepatitis B virus antigen binding molecules and uses thereof

Country Status (8)

Country Link
US (2) US10604559B2 (https=)
EP (1) EP3274051A4 (https=)
JP (1) JP6882184B2 (https=)
KR (1) KR102558839B1 (https=)
CN (1) CN107921285B (https=)
AU (1) AU2016238246B2 (https=)
CA (1) CA2980751A1 (https=)
WO (1) WO2016154593A1 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6721505B2 (ja) 2013-09-05 2020-07-15 アイジーエム バイオサイエンシズ インコーポレイテッド 定常領域が修飾された（ｃｏｎｓｔａｎｔ ｃｈａｉｎ ｍｏｄｉｆｉｅｄ）二重特異性五価及び六価Ｉｇ−Ｍ抗体
JP2017512208A (ja) 2014-02-10 2017-05-18 アイジーエム バイオサイエンス， インコーポレイテッド ＩｇＡ多重特異性結合分子
IL292311A (en) 2014-04-03 2022-06-01 Igm Biosciences Inc J-chain qualified
PT3247728T (pt) 2015-01-20 2020-07-16 Igm Biosciences Inc Moléculas de ligação do recetor da superfamília do fator de necrose tumoral (fnt) e utilização das mesmas
KR102357312B1 (ko) 2015-03-04 2022-02-03 아이쥐엠 바이오사이언스 인코포레이티드 Ｃｄ20 결합 분자 및 그의 용도
WO2016154593A1 (en) 2015-03-25 2016-09-29 Igm Biosciences, Inc. Multi-valent hepatitis b virus antigen binding molecules and uses thereof
WO2016168758A1 (en) 2015-04-17 2016-10-20 Igm Biosciences, Inc. Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof
EP3824903A1 (en) 2015-09-30 2021-05-26 IGM Biosciences Inc. Binding molecules with modified j-chain
EP3356401B1 (en) 2015-09-30 2020-06-24 IGM Biosciences, Inc. Binding molecules with modified j-chain
JP6979971B2 (ja) 2016-05-09 2021-12-15 アイジーエム バイオサイエンシズ インコーポレイテッド 抗ｐｄ−ｌ１抗体
US11401337B2 (en) 2017-04-07 2022-08-02 Igm Biosciences, Inc. Modified human IgM constant regions for modulation of complement-dependent cytolysis effector function
CN111787951B (zh) 2018-03-01 2025-06-17 Igm生物科学股份有限公司 影响IgM血清半衰期的IgM Fc和J链突变
KR20210083260A (ko) * 2018-10-23 2021-07-06 아이쥐엠 바이오사이언스 인코포레이티드 다가 IgM- 및 IgA-Fc 기반 결합 분자
US20230250192A1 (en) * 2019-05-15 2023-08-10 Kymab Limited Improved lambda antibodies
MX2022001934A (es) 2019-08-15 2022-03-11 Igm Biosciences Inc Moleculas de union multimericas inmunoestimuladoras.
BR112022021392A2 (pt) 2020-04-22 2022-12-06 Igm Biosciences Inc Moléculas de ligação multiméricas de agonista de pd-1
EP4188951A4 (en) * 2020-07-27 2024-08-28 IGM Biosciences, Inc. Multimeric coronavirus binding molecules and uses thereof
KR102674098B1 (ko) * 2021-01-14 2024-06-12 (주)옵토레인 스위칭 펩티드 및 이를 이용한 멀티플렉스 면역분석 방법
WO2022212191A1 (en) * 2021-04-01 2022-10-06 Modernatx, Inc. Mucosal expression of antibody structures and isotypes by mrna
KR102680147B1 (ko) * 2021-06-15 2024-07-03 에이피트바이오 주식회사 B형 간염바이러스 preS1항원의 간세포 수용체 결합부위에 특이적으로 결합하는 인간 항체 및 이의 용도
US20240391979A1 (en) * 2021-09-13 2024-11-28 Achelois Biopharma, Inc. Hepatitis b virus antivirus (hbv-antivirus) compositions and methods of use
US12600801B2 (en) 2022-07-11 2026-04-14 Fred Hutchinson Cancer Center Single-domain antibodies that bind ROR1
CN116640208B (zh) * 2023-06-01 2025-02-07 重庆医科大学 一种乙肝核心抗原单链抗体噬菌体文库及其构建与应用
CN117624340B (zh) * 2024-01-23 2024-04-30 北京臻知医学科技有限责任公司 识别人乙型肝炎病毒（hbv）抗原的t细胞受体（tcr）及其用途
CN121405821B (zh) * 2025-12-30 2026-04-10 山东大学 一种融合蛋白及在制备治疗或预防乙肝病毒产品中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4433059A (en) * 1981-09-08 1984-02-21 Ortho Diagnostic Systems Inc. Double antibody conjugate
US20020058247A1 (en) * 2000-04-21 2002-05-16 Matti Sallberg Synthetic peptides that bind to the hepatitis B virus core and e antigens

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6358260A (ja) * 1986-08-29 1988-03-14 Chemo Sero Therapeut Res Inst ＩｇＭ型抗体の測定法
US5061619A (en) * 1987-11-05 1991-10-29 Connaught Laboratories Limited Immunoassay using antibody-antigen conjugates
CA2064972A1 (en) * 1991-04-03 1992-10-04 John Joseph Rejman Immunoassay for immunoglobulins
GB9401987D0 (en) 1994-02-02 1994-03-30 Imperial College Modified nucleic acid
GB9608626D0 (en) 1996-04-25 1996-07-03 Univ College Of London Hepatitis b monoclonal antibodies
US6063905A (en) * 1997-01-07 2000-05-16 Board Of Regents, The University Of Texas System Recombinant human IGA-J. chain dimer
KR100345463B1 (ko) 1998-11-19 2003-01-08 주)녹십자 B형간염바이러스의표면항원프리-s1에대한인간화항체및이의제조방법
EP1532175B1 (en) 2002-03-22 2012-10-17 Aprogen, Inc. Humanized antibody and process for preparing the same
US20050014932A1 (en) 2003-05-15 2005-01-20 Iogenetics, Llc Targeted biocides
ATE490787T1 (de) 2003-07-15 2010-12-15 Chugai Pharmaceutical Co Ltd Produktion von igm durch transformierte zellen und verfahren zur quantifizierung dieser igm- produktion
CN1600856A (zh) * 2003-09-26 2005-03-30 陕西九州科技股份有限公司 分泌抗乙肝人单克隆抗体的异种杂交瘤细胞系的构建方法
CN101098889A (zh) 2004-11-05 2008-01-02 盘林京有限公司 抗体导致的细胞膜损伤
PL2112158T3 (pl) * 2007-04-20 2012-03-30 Hoffmann La Roche Wykrywanie pierwotnych infekcji wywołanych patogenami
WO2011045079A1 (en) 2009-10-15 2011-04-21 Intercell Ag Hepatitis b virus specific human antibodies
CN102321720B (zh) * 2011-07-28 2014-09-03 万晓春 一种混合细胞培养生产纯人源单克隆抗体的方法
JP6205363B2 (ja) * 2011-09-26 2017-09-27 ジェイエヌ バイオサイエンシーズ エルエルシー ハイブリッド定常領域
TWI606064B (zh) 2012-02-08 2017-11-21 Ｉｇｍ生物科技公司 細胞死亡誘導分子（ｃｄｉｍ）結合蛋白類及彼等之用途
CN104684928A (zh) * 2012-08-02 2015-06-03 Jn生物科学有限责任公司 通过半胱氨酸突变和μ尾端多聚化的抗体或融合蛋白
JP2016504015A (ja) 2012-09-27 2016-02-12 クルセル ホランド ベー ヴェー Ｂ型肝炎ウイルスに結合し、かつ中和することができるヒト結合分子およびその使用
JP6721505B2 (ja) 2013-09-05 2020-07-15 アイジーエム バイオサイエンシズ インコーポレイテッド 定常領域が修飾された（ｃｏｎｓｔａｎｔ ｃｈａｉｎ ｍｏｄｉｆｉｅｄ）二重特異性五価及び六価Ｉｇ−Ｍ抗体
SG10201806025TA (en) 2014-01-16 2018-08-30 Mario Umberto Francesco Mondelli Neutralizing human monoclonal antibodies against hepatitis b virus surface antigen
JP2017512208A (ja) 2014-02-10 2017-05-18 アイジーエム バイオサイエンス， インコーポレイテッド ＩｇＡ多重特異性結合分子
IL292311A (en) 2014-04-03 2022-06-01 Igm Biosciences Inc J-chain qualified
PT3247728T (pt) 2015-01-20 2020-07-16 Igm Biosciences Inc Moléculas de ligação do recetor da superfamília do fator de necrose tumoral (fnt) e utilização das mesmas
KR102357312B1 (ko) * 2015-03-04 2022-02-03 아이쥐엠 바이오사이언스 인코포레이티드 Ｃｄ20 결합 분자 및 그의 용도
WO2016154593A1 (en) 2015-03-25 2016-09-29 Igm Biosciences, Inc. Multi-valent hepatitis b virus antigen binding molecules and uses thereof
WO2016168758A1 (en) 2015-04-17 2016-10-20 Igm Biosciences, Inc. Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof
EP3824903A1 (en) 2015-09-30 2021-05-26 IGM Biosciences Inc. Binding molecules with modified j-chain
EP3356401B1 (en) 2015-09-30 2020-06-24 IGM Biosciences, Inc. Binding molecules with modified j-chain
JP6979971B2 (ja) 2016-05-09 2021-12-15 アイジーエム バイオサイエンシズ インコーポレイテッド 抗ｐｄ−ｌ１抗体
AU2017300647A1 (en) 2016-07-20 2019-02-07 Igm Biosciences, Inc. Multimeric GITR binding molecules and uses thereof
EP3487298A4 (en) 2016-07-20 2020-03-11 IGM Biosciences, Inc. MULTIMERE CD137 / 4-1BB-BINDING MOLECULES AND USES THEREOF
EP3496536A4 (en) 2016-07-20 2020-02-12 IGM Biosciences, Inc. MULTIMERE CD40-BINDING MOLECULES AND USES THEREOF
JP2019530640A (ja) 2016-07-20 2019-10-24 アイジーエム バイオサイエンシズ インコーポレイテッド 多量体ｏｘ４０結合分子及びその使用
US11401337B2 (en) 2017-04-07 2022-08-02 Igm Biosciences, Inc. Modified human IgM constant regions for modulation of complement-dependent cytolysis effector function
AU2019224136A1 (en) 2018-02-26 2020-09-10 Igm Biosciences, Inc. Use of a multimeric anti-DR5 binding molecule in combination with a chemotherapeutic agent for treating cancer
CN111787951B (zh) 2018-03-01 2025-06-17 Igm生物科学股份有限公司 影响IgM血清半衰期的IgM Fc和J链突变
KR20210083260A (ko) 2018-10-23 2021-07-06 아이쥐엠 바이오사이언스 인코포레이티드 다가 IgM- 및 IgA-Fc 기반 결합 분자
US20220106398A1 (en) 2019-02-08 2022-04-07 Igm Biosciences, Inc. Anti-gitr antigen-binding domains and uses thereof
MX2022001934A (es) 2019-08-15 2022-03-11 Igm Biosciences Inc Moleculas de union multimericas inmunoestimuladoras.
WO2021034646A1 (en) 2019-08-17 2021-02-25 Igm Biosciences, Inc. Multimeric bispecific anti-cd123 binding molecules and uses thereof
KR20220050166A (ko) 2019-08-23 2022-04-22 아이쥐엠 바이오사이언스 인코포레이티드 Igm 글리코변이체
CN114616031A (zh) 2019-09-19 2022-06-10 Igm生物科学股份有限公司 对靶标密度高的细胞的选择性增强的多聚体抗体
IL293739A (en) 2020-01-06 2022-08-01 Igm Biosciences Inc Highly sialic acid-modified multimeric binding compounds
BR112022021392A2 (pt) 2020-04-22 2022-12-06 Igm Biosciences Inc Moléculas de ligação multiméricas de agonista de pd-1
JP2023526224A (ja) 2020-05-12 2023-06-21 アイジーエム バイオサイエンシズ インコーポレイテッド がんを治療するための、がん治療薬との組合せでの多量体抗ｄｒ５結合分子の使用
EP4188951A4 (en) 2020-07-27 2024-08-28 IGM Biosciences, Inc. Multimeric coronavirus binding molecules and uses thereof
US20240002526A1 (en) 2020-11-17 2024-01-04 Igm Biosciences, Inc. Uses of effector cell engaging molecules with moieties of differing potencies

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4433059A (en) * 1981-09-08 1984-02-21 Ortho Diagnostic Systems Inc. Double antibody conjugate
US20020058247A1 (en) * 2000-04-21 2002-05-16 Matti Sallberg Synthetic peptides that bind to the hepatitis B virus core and e antigens

Also Published As

Publication number Publication date
US10604559B2 (en) 2020-03-31
US11535664B2 (en) 2022-12-27
AU2016238246A1 (en) 2017-10-12
WO2016154593A1 (en) 2016-09-29
EP3274051A4 (en) 2018-08-22
EP3274051A1 (en) 2018-01-31
KR102558839B1 (ko) 2023-07-25
JP6882184B2 (ja) 2021-06-02
JP2018513680A (ja) 2018-05-31
CN107921285A (zh) 2018-04-17
KR20180012245A (ko) 2018-02-05
US20210002353A1 (en) 2021-01-07
CA2980751A1 (en) 2016-09-29
US20180118814A1 (en) 2018-05-03
CN107921285B (zh) 2022-06-07

Similar Documents

Publication Publication Date Title
US11535664B2 (en) Multi-valent hepatitis B virus antigen binding molecules and uses thereof
JP7796918B2 (ja) エボラウイルス糖タンパク質に対するヒト抗体
JP7297814B2 (ja) 中東呼吸器症候群－コロナウイルススパイクタンパク質に対するヒト抗体
US12037381B2 (en) Antibodies that potently neutralize hepatitis B virus and uses thereof
US20250353900A1 (en) Antibodies that neutralize hepatitis b virus and uses thereof
HK40074417A (en) Antibodies that neutralize hepatitis b virus and uses thereof
HK40074418A (en) Antibodies that neutralize hepatitis b virus and uses thereof
HK1256869B (en) Antibodies that potently neutralize hepatitis b virus and uses thereof

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: IGM BIOSCIENCES A/S

Free format text: FORMER APPLICANT(S): IGM BIOSCIENCES, INC.

PC1 Assignment before grant (sect. 113)

Owner name: IGM BIOSCIENCES, INC.

Free format text: FORMER APPLICANT(S): IGM BIOSCIENCES A/S

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired